ELIGIBILITY AND COST OF LOW-DOSE RIVAROXABAN BASED ON COMPASS TRIAL: INSIGHTS FROM THE VETERANS AFFAIRS HEALTHCARE SYSTEMAkash Kataruka, Michael E. DeBakey, Julia M. Akeroyd et al.|Journal of the American College of Cardiology|2020Cited by 0